Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheimer’s disease, according to new Phase 2 CELIA study data.
Presenters shared the Week 96 findings at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference.
The results showed that diranersen, an antisense oligonucleotide (ASO) therapy targeting tau, delivered increasing clinical benefits across measures of cognition, function and disease progression.
Twice-Yearly Regimen Generates Largest Two-Year Effects
At two years, analyses confirmed that diranersen continued slowing clinical decline across cognition, function and disease progression. Investigators observed clinical benefits across all studied doses, with the 60 mg twice-yearly regimen producing the largest treatment effects.
Patients generally tolerated diranersen well through two years, and researchers detected no new safety signals.
The two-year analyses originated from CELIA’s ongoing open-label extension phase.
To determine treatment effects, researchers compared participants who took diranersen during the initial placebo-controlled phase and remained on that same dose through two years against participants who initially received placebo.
At Week 96, participants who started on placebo and later transitioned into the extension phase had received either zero doses or a single dose of diranersen.
This group provided a placebo-equivalent comparator for the two-year analysis, and Biogen expects all extension phase participants to receive diranersen as the study progresses.
18-Month Biomarker And Cognitive Subgroup Findings
Alongside the two-year results, Biogen presented new 18-month placebo-controlled clinical and biomarker findings from CELIA that further support diranersen’s effects.
At 18 months, a subgroup analysis of the twice-yearly 60 mg diranersen regimen demonstrated preferential efficacy in memory, orientation, and executive function.
Furthermore, diranersen reduced tau PET signals broadly across the brain. The investigational therapy also lowered levels of CSF p-tau181 and plasma p-tau217.
Supporting Continued Early Alzheimer’s Development
These new findings build upon previously reported results from the Phase 2 CELIA study.
The therapy also demonstrated reductions in cerebrospinal fluid tau levels and tau pathology measured through positron emission tomography scans across all dose groups.
However, CELIA did not achieve its primary endpoint, which evaluated dose response for change from baseline on the Clinical Dementia Rating–Sum of Boxes (measures cognitive and functional impairment) scale at Week 76.
In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize diranersen.
BIIB Price Action: Biogen shares were down 0.59% at $249.31 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by JHVEPhoto via Shutterstock
